Skip to main content
Explore URMC


Prostate Cancer: ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS)

Research Question:
Is Darolutamide (ODM-201) effective at keeping your cancer under control when given in addition to standard treatment which includes androgen deprivation therapy (ADT) and docetaxel chemotherapy?

Basic Study Information

You will be randomly assigned to a treatment group, Darolutamide (ODM-201) or placebo. You will have a 1:1 chance of receiving Darolutamide (ODM-201) and a 1:1 chance of receiving placebo.

Location: Cancer Center
Study Web URL:
Study Reference #: IGUP16141

Lead Researcher (Principal Investigator)

Lead Researcher: Elizabeth Guancial

Study Contact Information

Study Coordinator: Ayesha Khan
Phone: (585) 275-3351

Additional Study Details

Learn More About These Conditions

More information about Prostate Cancer

Return to Search